TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 130.1% in July

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 32,900 shares, an increase of 130.1% from the June 30th total of 14,300 shares. Based on an average trading volume of 881,700 shares, the days-to-cover ratio is currently 0.0 days.

TC Biopharm Stock Up 4.7 %

Shares of NASDAQ TCBP opened at $0.90 on Friday. TC Biopharm has a 52 week low of $0.72 and a 52 week high of $19.60. The stock has a 50 day moving average price of $0.95 and a 200 day moving average price of $1.29. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.88 and a quick ratio of 0.88.

TC Biopharm’s stock is going to reverse split before the market opens on Monday, August 5th. The 1-10 reverse split was announced on Monday, August 5th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 5th.

TC Biopharm (NASDAQ:TCBP) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($2.80) EPS for the quarter.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.